MTOR and skin squamous cell carcinoma: A randomized clinical trial in post-kidney transplant patients comparing calcineurin inhibitor (cyclosporine) to mTOR inhibitor (sirolimus) found a lower incidence of recurrent CSCC in the group receiving sirolimus, and there was no difference in the graft rejection rate [60].